恩格列净对急性心肌梗死后心力衰竭结局的影响:EMPACT-MI 试验分析
EMPACT-MI 试验随机分配 6522 例急性心肌梗死且伴新发左室射血分数<45% 或淤血症状/体征的患者,在入院 14 天内接受恩格列净 10 mg 每日一次或安慰剂。中位随访 17.9 个月,恩格列净组首次心衰住院和总心衰住院风险均显著低于安慰剂组,且出院后新启用利尿剂、肾素-血管紧张素调节剂或盐皮质激素受体拮抗剂的需求更少。
要点
- 恩格列净降低急性心梗后首次心衰住院风险(HR 0.77,95%CI 0.60–0.98,P=0.031)。
- 恩格列净降低总心衰住院风险(率比 0.67,95%CI 0.51–0.89,P=0.006)。
- 恩格列净组出院后新启用利尿剂、肾素-血管紧张素调节剂或醛固酮受体拮抗剂更少(均 P<0.05)。
核心结论
- 恩格列净降低急性心肌梗死后左室功能不全或淤血患者的心衰风险。
研究设计与样本
- EMPACT-MI 为双盲、随机、安慰剂对照、事件驱动试验,随机分配 6522 例因急性心肌梗死住院且有心衰风险的患者。
- 入组标准为新发左室射血分数<45% 或淤血症状/体征,入院 14 天内给予恩格列净 10 mg 每日一次或安慰剂。
- 本次分析为预设次要分析,分析心衰结局,中位随访 17.9 个月。
主要发现
- 首次心衰住院:恩格列净组 118 例(3.6%)vs 安慰剂组 153 例(4.7%),HR 0.77(95%CI 0.60–0.98),P=0.031。
- 总心衰住院:恩格列净组 148 次 vs 安慰剂组 207 次,率比 0.67(95%CI 0.51–0.89),P=0.006。
- 亚组分析显示恩格列净对首次和总心衰住院的获益在临床相关亚组中一致。
- 出院后新启用利尿剂、肾素-血管紧张素调节剂或盐皮质激素受体拮抗剂的需求恩格列净组少于安慰剂组(均 P<0.05)。
临床怎么用
- 对急性心肌梗死后伴左室功能不全或淤血的患者,可考虑尽早(入院 14 天内)使用恩格列净 10 mg 每日一次以降低心衰住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction. Whereas the EMPACT-MI trial (Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients With Acute Myocardial Infarction) showed that empagliflozin does not reduce the risk of the composite of hospitalization for HF and all-cause death, the effect of empagliflozin on first and recurrent HF events after myocardial infarction is unknown. METHODS: EMPACT-MI was a double-blind, randomized, placebo-controlled, event-driven trial that randomized 6522 patients hospitalized for acute myocardial infarction at risk for HF on the basis of newly developed left ventricular ejection fraction of <45% or signs or symptoms of congestion to receive empagliflozin 10 mg daily or placebo within 14 days of admission. In prespecified secondary analyses, treatment groups were analyzed for HF outcomes. RESULTS: Over a median follow-up of 17.9 months, the risk for first HF hospitalization and total HF hospitalizations was significantly lower in the empagliflozin compared with the placebo group (118 [3.6%] versus 153 [4.7%] patients with events; hazard ratio, 0.77 [95% CI, 0.60, 0.98]; P=0.031, for first HF hospitalization; 148 versus 207 events; rate ratio, 0.67 [95% CI, 0.51, 0.89]; P=0.006, for total HF hospitalizations). Subgroup analysis showed consistency of empagliflozin benefit across clinically relevant patient subgroups for first and total HF hospitalizations. The need for new use of diuretics, renin-angiotensin modulators, or mineralocorticoid receptor antagonists after discharge was less in patients randomized to empagliflozin versus placebo (all P<0.05). CONCLUSIONS: Empagliflozin reduced the risk of HF in patients with left ventricular dysfunction or congestion after acute myocardial infarction. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04509674.
引用
- Hernandez, Udell, Jones, et al. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. Circulation. 2024. PMID: 38581389. doi:10.1161/CIRCULATIONAHA.124.069217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。